Literature DB >> 20499110

Association between adherence to evidence-based guidelines for the prescription of non-steroidal anti-inflammatory drugs and the incidence of gastric mucosal lesions in Japanese patients.

Hidetaka Tsumura1, Tsuyoshi Fujita, Isamu Tamura, Yoshinori Morita, Masaru Yoshida, Takashi Toyonaga, Hidekazu Mukai, Hideto Inokuchi, Hiromu Kutsumi, Takeshi Azuma.   

Abstract

OBJECTIVE: Recently, guidelines for the treatment and prevention of ulcers induced by non-steroidal anti-inflammatory drugs (NSAIDs) were established. This study investigated the association between the current adherence to the guidelines and the incidence of gastric mucosal lesions caused by NSAIDs.
METHODS: This study included 254 NSAIDs users (128 regular and 126 on-demand users) who had undergone upper gastrointestinal endoscopy. The patients were characterized as high risk based on the following: age 65 years or older, history of peptic ulcers, concurrent use of corticosteroids or anticoagulants, and high-dose NSAIDs use. Adherence was defined as the prescription of NSAIDs with proton pump inhibitors, prostaglandin analogues, or high-dose histamine 2 receptor antagonists in high-risk NSAIDs user. The severity of gastric mucosal lesions was evaluated using the modified LANZA score (MLS).
RESULTS: Seventy-nine (61.7%) of the regular NSAIDs users and 65 (51.6%) of the on-demand NSAIDs users met our definition of high-risk patients. Adherence in the regular NSAIDs users and on-demand NSAIDs users was 25 (31.7%) and 16 (24.6%), respectively. The incidence of gastric mucosal lesions (MLS ≧ 1) was significantly higher in the nonadherence group than in the adherence group for both regular NSAIDs users (59.3 vs. 28.0%, P = 0.01) and on-demand NSAIDs users (63.3 vs. 25.0%, P = 0.01). Gastric ulcers in the regular NSAIDs users were more frequently observed in the nonadherence group than in the adherence group (29.6 vs. 4.0%, P < 0.01).
CONCLUSION: Nonadherence was associated with a high prevalence of NSAIDs-induced gastric mucosal lesions.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20499110     DOI: 10.1007/s00535-010-0236-2

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  34 in total

1.  Quality indicators for the management of osteoarthritis in vulnerable elders.

Authors:  C H MacLean
Journal:  Ann Intern Med       Date:  2001-10-16       Impact factor: 25.391

2.  National adherence to evidence-based guidelines for the prescription of nonsteroidal anti-inflammatory drugs.

Authors:  Neena S Abraham; Hashem B El-Serag; Michael L Johnson; Christine Hartman; Peter Richardson; Wayne A Ray; Walter Smalley
Journal:  Gastroenterology       Date:  2005-10       Impact factor: 22.682

3.  Prescription of nonsteroidal anti-inflammatory drugs and co-prescribed drugs for mucosal protection: analysis of the present status based on questionnaires obtained from orthopedists in Japan.

Authors:  Hidetaka Tsumura; Isamu Tamura; Hiroshi Tanaka; Ryo Chinzei; Tsukasa Ishida; Atsuhiro Masuda; Hideyuki Shiomi; Yoshinori Morita; Masaru Yoshida; Hiromu Kutsumi; Hideto Inokuchi; Minoru Doita; Masahiro Kurosaka; Takeshi Azuma
Journal:  Intern Med       Date:  2007-07-02       Impact factor: 1.271

4.  Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis.

Authors:  Jia Qing Huang; Subbaramiah Sridhar; Richard H Hunt
Journal:  Lancet       Date:  2002-01-05       Impact factor: 79.321

5.  A guideline for the treatment and prevention of NSAID-induced ulcers. Members of the Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology.

Authors:  F L Lanza
Journal:  Am J Gastroenterol       Date:  1998-11       Impact factor: 10.864

6.  Peptic ulcer bleeding: accessory risk factors and interactions with non-steroidal anti-inflammatory drugs.

Authors:  J Weil; M J Langman; P Wainwright; D H Lawson; M Rawlins; R F Logan; T P Brown; M P Vessey; M Murphy; D G Colin-Jones
Journal:  Gut       Date:  2000-01       Impact factor: 23.059

7.  Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data.

Authors:  Rikke Sørensen; Morten L Hansen; Steen Z Abildstrom; Anders Hvelplund; Charlotte Andersson; Casper Jørgensen; Jan K Madsen; Peter R Hansen; Lars Køber; Christian Torp-Pedersen; Gunnar H Gislason
Journal:  Lancet       Date:  2009-12-12       Impact factor: 79.321

8.  Nonsteroidal anti-inflammatory drug-associated gastropathy: incidence and risk factor models.

Authors:  J F Fries; C A Williams; D A Bloch; B A Michel
Journal:  Am J Med       Date:  1991-09       Impact factor: 4.965

9.  A comparative endoscopic evaluation of the damaging effects of nonsteroidal anti-inflammatory agents on the gastric and duodenal mucosa.

Authors:  F L Lanza; G L Royer; R S Nelson; T T Chen; C E Seckman; M F Rack
Journal:  Am J Gastroenterol       Date:  1981-01       Impact factor: 10.864

10.  Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis.

Authors:  S E Gabriel; L Jaakkimainen; C Bombardier
Journal:  Ann Intern Med       Date:  1991-11-15       Impact factor: 25.391

View more
  3 in total

1.  Interobserver variation in the endoscopic diagnosis of gastroduodenal ulcer scars: implications for clinical management of NSAIDs users.

Authors:  Yuji Amano; Goichi Uno; Takafumi Yuki; Mayumi Okada; Yasumasa Tada; Nobuhiko Fukuba; Norihisa Ishimura; Shunji Ishihara; Yoshikazu Kinoshita
Journal:  BMC Res Notes       Date:  2011-10-13

Review 2.  Adherence to the preventive strategies for nonsteroidal anti-inflammatory drug- or low-dose aspirin-induced gastrointestinal injuries.

Authors:  Tsuyoshi Fujita; Hiromu Kutsumi; Tsuyoshi Sanuki; Takanobu Hayakumo; Takeshi Azuma
Journal:  J Gastroenterol       Date:  2013-03-05       Impact factor: 7.527

Review 3.  Nonsteroidal anti-inflammatory drugs, gastroprotection, and benefit-risk.

Authors:  Robert Andrew Moore; Sheena Derry; Lee S Simon; Paul Emery
Journal:  Pain Pract       Date:  2013-08-14       Impact factor: 3.183

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.